BioSpace News Archive

HI-Bio Launches with $120M and Two MorphoSys Assets in Immune-Mediated Space - Updated

With $120 million in backing, HI-Bio launched two assets licensed from MorphoSys AG, including the anti-CD38 antibody felzartamab and HIB210, aimed at severe immune-mediated diseases.

November 1, 2022
·
3 min read
·
Alex Keown
Drug Development

Unity Bio Set to Launch Pivotal DME Study after Significant Data

Unity announced advances in diabetic macular edema via Phase II study results, potentially allowing its recipients to return to tasks of daily living, like driving.

November 1, 2022
·
2 min read
·
Alex Keown
Business

J&J Expands Cardiovascular Business with $16.6B Abiomed Acquisition

Johnson & Johnson announced it was acquiring all outstanding shares of Abiomed for $16.6 billion to expand Abiomed’s cardiovascular technologies and increase patient access.

November 1, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Verge Genomics and Stealth Bio Advance Novel Therapeutics in ALS

Verge Genomics dosed its first patient in a Phase I trial studying VRG50635, while Stealth Bio’s SBT-272 was granted Orphan Drug designation by the FDA.

November 1, 2022
·
2 min read
·
Rosemary Scott
Pharm Country

New York City Latest to Mandate Salary Ranges in Job Postings

A new municipal law took effect Tuesday in New York City, requiring companies with four or more employees to include a specific pay range in every job posting.

November 1, 2022
·
1 min read
·
BioSpace Editorial Staff
Drug Development

Pfizer’s Maternal RSV Vaccine Protects Newborns from Severe Disease

In a Phase III trial, Pfizer’s RSVpreF, a bivalent RSV vaccine, protected infants against severe medically attended lower respiratory tract illness when administered during the second or third trimester.

November 1, 2022
·
2 min read
·
Mark Terry
Affimed to Present at the 2022 Jefferies London Healthcare Conference

Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.

November 1, 2022
·
1 min read
Business

Bio-Techne Releases First Quarter Fiscal 2023 Results

Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2022.

November 1, 2022
·
20 min read
Business

ImmunoGen Announces Departure of Chief Commercial Officer - November 01, 2022

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Kristen Harrington-Smith, Senior Vice President and Chief Commercial Officer, will be departing the Company.

November 1, 2022
·
4 min read
Business

IDEXX Laboratories Announces Third Quarter 2022 Results

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced third quarter results and an update on U.S. companion animal diagnostics trends.

November 1, 2022
·
33 min read